CompletedNCT02579928
Single Ketamine Infusion for Adolescents With Depression or Anxiety
About this title
Read the official source — NCT02579928Medication studyAges 13–17United States
Understand this study
Who was this study for?
Listed age limits: 13 years to 17 years.
- Listed locations
- New Haven and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 17
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT02579928
- Official title
Show the full official title
Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including ketamine and Midazolam.
Who was this study for?
Listed age limits: 13 years to 17 years.
